Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection
- PMID: 23478961
- PMCID: PMC3632900
- DOI: 10.1128/AAC.02176-12
Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection
Abstract
The rising incidence of Clostridium difficile infection (CDI) could be reduced by lowering exposure to high-risk antibiotics. The objective of this study was to determine the association between antibiotic class and the risk of CDI in the community setting. The EMBASE and PubMed databases were queried without restriction to time period or language. Comparative observational studies and randomized controlled trials (RCTs) considering the impact of exposure to antibiotics on CDI risk among nonhospitalized populations were considered. We estimated pooled odds ratios (OR) for antibiotic classes using random-effect meta-analysis. Our search criteria identified 465 articles, of which 7 met inclusion criteria; all were observational studies. Five studies considered antibiotic risk relative to no antibiotic exposure: clindamycin (OR = 16.80; 95% confidence interval [95% CI], 7.48 to 37.76), fluoroquinolones (OR = 5.50; 95% CI, 4.26 to 7.11), and cephalosporins, monobactams, and carbapenems (CMCs) (OR = 5.68; 95% CI, 2.12 to 15.23) had the largest effects, while macrolides (OR = 2.65; 95% CI, 1.92 to 3.64), sulfonamides and trimethoprim (OR = 1.81; 95% CI, 1.34 to 2.43), and penicillins (OR = 2.71; 95% CI, 1.75 to 4.21) had lower associations with CDI. We noted no effect of tetracyclines on CDI risk (OR = 0.92; 95% CI, 0.61 to 1.40). In the community setting, there is substantial variation in the risk of CDI associated with different antimicrobial classes. Avoidance of high-risk antibiotics (such as clindamycin, CMCs, and fluoroquinolones) in favor of lower-risk antibiotics (such as penicillins, macrolides, and tetracyclines) may help reduce the incidence of CDI.
Figures
Comment in
-
Are there reasons to prefer tetracyclines to macrolides in older patients with community-acquired pneumonia?Antimicrob Agents Chemother. 2013 Aug;57(8):4093. doi: 10.1128/AAC.00828-13. Antimicrob Agents Chemother. 2013. PMID: 23858063 Free PMC article. No abstract available.
-
Reply to "Are there reasons to prefer tetracyclines to macrolides in older patients with community-acquired pneumonia?".Antimicrob Agents Chemother. 2013 Aug;57(8):4094. doi: 10.1128/AAC.00864-13. Antimicrob Agents Chemother. 2013. PMID: 23858064 Free PMC article. No abstract available.
References
-
- Kwong J, Crowcroft N, Campitelli M, Daneman N, Deeks S, Manuel D. 2010. Ontario Burden of Infectious Disease Study (ONBOIDS): an OAHPP/ICES report. Ontario Agency for Health Protection and Promotion and Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada
-
- Dubberke ER, Reske KA, Olsen MA, McMullen KM, Mayfield JL, McDonald LC, Fraser VJ. 2007. Evaluation of Clostridium difficile-associated disease pressure as a risk factor for C. difficile-associated disease. Arch. Intern. Med. 167:1092–1097 - PubMed
-
- Centers for Disease Control and Prevention 2005. Severe Clostridium difficile-associated disease in populations previously at low risk–four states, 2005. Morb. Mortal. Wkly. Rep. 54:1201–1205 - PubMed
-
- Bauer MP, Veenendaal D, Verhoef L, Bloembergen P, Van Dissel JT, Kuijper EJ. 2009. Clinical and microbiological characteristics of community-onset Clostridium difficile infection in The Netherlands. Clin. Microbiol. Infect. 15:1087–1092 - PubMed
-
- Rangaiah J, Wilks M, Millar M. 2009. Community Clostridium difficile. BMJ 338:b1346 doi:10.1136/bmj.b2195 - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
